Page URL:

Loss of two genes may drive serrated colorectal cancers

17 December 2018
Appeared in BioNews 980

Two genetic markers linked to an aggressive, treatment-resistant form of colorectal cancer.

Serrated tumours are harder to treat than other colorectal cancers, and clinicians frequently struggle to differentiate between serrated and non-serrated tumours. More than a third of colorectal cancers arise from serrated polyps in the colon.

'Our study identified two genetic markers that may clearly identify this colon cancer subgroup and offer an effective precision medicine treatment option,' said study author Dr Darren Sigal, program director of gastrointestinal oncology at Scripps MD Anderson Cancer Center.

The researchers identified the genes in experiments in mice. When mice lacked two genes – which encode protein kinase C lambda/iota and protein kinase C zeta – they spontaneously developed serrated colorectal cancer. Human tissue samples from colorectal cancer patients also showed lowered expression of these proteins compared with samples from cancer-free people.

As well as finding a biomarker for serrated colorectal cancer, the researchers also found a potential treatment combination that could tackle the condition.

Losing the two genes led to a protein called PD-L1 infiltrating the tissue surrounding a serrated tumour. This protein is known to mask cancerous cells from immune cells. When the researchers applied two compounds – TGF-beta receptor inhibitor and anti-PD-L1 – to the tumours, the PD-L1 levels decreased and immune response improved.

'Our findings identify both a promising combination treatment for serrated colorectal cancer and potential biomarkers that can identify this cancer subtype – both of which are urgently needed,' says Dr Jorge Moscat, study author and director and professor in Sanford Burnam Prebys's Cancer Metabolism and Signaling Networks Program.

'Additionally, the mouse model we created closely mirrors the human disease, an important step that could help reveal more insights into this deadly cancer.'

The research was published in the journal Immunity.

Colorectal cancer: loss of two genes may drive tumour formation
MedicalNewsToday |  13 December 2018
Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment
Sanford Burnham Prebys Medical Discovery Institute |  11 December 2018
Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance
Immunity |  11 December 2018
13 September 2021 - by Manon Everard 
A lack of a specific gene in immune cells of patients with colon cancer has been linked with a much more dangerous form of the disease...
21 June 2021 - by Semyon Bodian 
A gene associated with ageing may aid precancerous cells in outcompeting healthy stem cells, new research has shown...
4 June 2018 - by Shaoni Bhattacharya 
A new blood test which can detect ten cancers at an early stage is offering hope as a way to screen for multiple cancers...
12 December 2016 - by Ayala Ochert and Ebtehal Moussa 
Researchers have successfully treated a woman with colon cancer using her own immune cells to target a cancer-causing gene that had previously been considered 'undruggable'...
7 March 2016 - by Paul Waldron 
A study in mice has shown that a diet high in fat can stimulate the production of stem cells in the intestine, which might then go on to form tumours...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.